With recent studies showing synthetic lethality of bromodomain inhibitors in combination with PARP inhibitors for the treatment of different tumor models51,75, understanding the role of BRD4 in regulating the replication stress DNA damage response may allow for the development of additional rational combination therapies using bromodomain inhibitors to improve treatment outcomes for a variety of cancers. This evidence concerns the gene BRD4 and cancer.